Cost-Effectiveness of Sacubitril–Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction
Authors: Jordan King, Adam Bress, Brandon Bellows
Journal: Annals of Internal Medicine (2017)

Letters18 April 2017Cost-Effectiveness of Sacubitril–Valsartan in Patients Who Have Heart Failure With Reduced Ejection FractionJordan King, PharmD, MS, Adam Bress, PharmD, MS, and Brandon Bellows, PharmD, MSJordan King, PharmD, MSFrom Kaiser Permanente Colorado, Aurora, Colorado, and University of Utah, Salt Lake City, Utah.Search for more papers by this author, Adam Bress, PharmD, MSFrom Kaiser Permanente Colorado, Aurora, Colorado, and University of Utah, Salt Lake City, Utah.Search for more papers by this author, and Brandon Bellows, PharmD, MSFrom Kaiser Permanente Colorado, Aurora, Colorado, and University of Utah, Salt Lake City, Utah.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0045 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read with great interest Sandhu and colleagues' cost-effectiveness analysis of sacubitril–valsartan therapy for New York Heart Association class II to IV heart failure and reduced ejection fraction (1). The authors concluded, as have 2 other recent analyses (2, 3), that this therapy seems to be a cost-effective treatment approach to reduce cardiovascular mortality and morbidity associated with these conditions. We applaud their thorough analysis, agree with their conclusion, and offer a comment to add to this important discussion.The 3 studies to date that have examined the cost-effectiveness of sacubitril–valsartan reported incremental cost-effectiveness ratios between $45 017 ...References1. Sandhu AT, Ollendorf DA, Chapman RH, Pearson SD, Heidenreich PA. Cost-effectiveness of sacubitril–valsartan in patients with heart failure with reduced ejection fraction. Ann Intern Med. 2016;165:681-9. [PMID: 27571284]. doi:10.7326/M16-0057 LinkGoogle Scholar2. King JB, Shah RU, Bress AP, Nelson RE, Bellows BK. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2016;4:392-402. [PMID: 27039128] doi:10.1016/j.jchf.2016.02.007 CrossrefMedlineGoogle Scholar3. Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, et al. Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol. 2016;1:666-72. [PMID: 27438344] doi:10.1001/jamacardio.2016.1747 CrossrefMedlineGoogle Scholar4. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al; PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. [PMID: 25176015] doi:10.1056/NEJMoa1409077 CrossrefMedlineGoogle Scholar5. Dreyer NA, Schneeweiss S, McNeil BJ, Berger ML, Walker AM, Ollendorf DA, et al; GRACE Initiative. GRACE principles: recognizing high-quality observational studies of comparative effectiveness. Am J Manag Care. 2010;16:467-71. [PMID: 20560690] MedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Kaiser Permanente Colorado, Aurora, Colorado, and University of Utah, Salt Lake City, Utah.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0045. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCost-Effectiveness of Sacubitril–Valsartan in Patients With Heart Failure With Reduced Ejection Fraction Alexander T. Sandhu , Daniel A. Ollendorf , Richard H. Chapman , Steven D. Pearson , and Paul A. Heidenreich Cost-Effectiveness of Sacubitril–Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction Alexander T. Sandhu , Daniel A. Ollendorf , Richard H. Chapman , Steven D. Pearson , and Paul A. Heidenreich Metrics 18 April 2017Volume 166, Issue 8Page: 606-607KeywordsCardiovascular therapyClinical trialsDisclosureEjection fractionHealth careHeart failureMorbidityMortality ePublished: 18 April 2017 Issue Published: 18 April 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...